SI2139483T1 - Kombinacijske terapije, obsegajoče PI3K-alfa kinoksalin inhibitor, za uporabo pri zdravljenju raka - Google Patents

Kombinacijske terapije, obsegajoče PI3K-alfa kinoksalin inhibitor, za uporabo pri zdravljenju raka

Info

Publication number
SI2139483T1
SI2139483T1 SI200831061T SI200831061T SI2139483T1 SI 2139483 T1 SI2139483 T1 SI 2139483T1 SI 200831061 T SI200831061 T SI 200831061T SI 200831061 T SI200831061 T SI 200831061T SI 2139483 T1 SI2139483 T1 SI 2139483T1
Authority
SI
Slovenia
Prior art keywords
pi3k
quinoxaline
cancer
inhibitor
alpha
Prior art date
Application number
SI200831061T
Other languages
English (en)
Slovenian (sl)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of SI2139483T1 publication Critical patent/SI2139483T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200831061T 2007-04-11 2008-04-08 Kombinacijske terapije, obsegajoče PI3K-alfa kinoksalin inhibitor, za uporabo pri zdravljenju raka SI2139483T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
EP08742674.8A EP2139483B9 (en) 2007-04-11 2008-04-08 Combination therapies comprising a quinoxaline inhibitor of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
SI2139483T1 true SI2139483T1 (sl) 2013-11-29

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831061T SI2139483T1 (sl) 2007-04-11 2008-04-08 Kombinacijske terapije, obsegajoče PI3K-alfa kinoksalin inhibitor, za uporabo pri zdravljenju raka

Country Status (34)

Country Link
US (1) US8481001B2 (US07794700-20100914-C00152.png)
EP (1) EP2139483B9 (US07794700-20100914-C00152.png)
JP (2) JP5726515B2 (US07794700-20100914-C00152.png)
KR (1) KR101586774B1 (US07794700-20100914-C00152.png)
CN (2) CN103202842A (US07794700-20100914-C00152.png)
AU (1) AU2008239668B2 (US07794700-20100914-C00152.png)
BR (1) BRPI0810208A2 (US07794700-20100914-C00152.png)
CA (1) CA2684056A1 (US07794700-20100914-C00152.png)
CO (1) CO6140024A2 (US07794700-20100914-C00152.png)
CR (1) CR11099A (US07794700-20100914-C00152.png)
CY (1) CY1114608T1 (US07794700-20100914-C00152.png)
DK (1) DK2139483T3 (US07794700-20100914-C00152.png)
EA (1) EA019064B1 (US07794700-20100914-C00152.png)
EC (1) ECSP099723A (US07794700-20100914-C00152.png)
ES (1) ES2438998T3 (US07794700-20100914-C00152.png)
GT (1) GT200900263A (US07794700-20100914-C00152.png)
HK (1) HK1140141A1 (US07794700-20100914-C00152.png)
HR (1) HRP20131081T1 (US07794700-20100914-C00152.png)
IL (1) IL201211A (US07794700-20100914-C00152.png)
MA (1) MA31335B1 (US07794700-20100914-C00152.png)
ME (1) ME00937B (US07794700-20100914-C00152.png)
MX (1) MX2009010929A (US07794700-20100914-C00152.png)
MY (1) MY150797A (US07794700-20100914-C00152.png)
NI (1) NI200900184A (US07794700-20100914-C00152.png)
NZ (1) NZ580009A (US07794700-20100914-C00152.png)
PL (1) PL2139483T3 (US07794700-20100914-C00152.png)
PT (1) PT2139483E (US07794700-20100914-C00152.png)
RS (1) RS53020B (US07794700-20100914-C00152.png)
SI (1) SI2139483T1 (US07794700-20100914-C00152.png)
SV (1) SV2009003390A (US07794700-20100914-C00152.png)
TN (1) TN2009000399A1 (US07794700-20100914-C00152.png)
UA (1) UA98141C2 (US07794700-20100914-C00152.png)
WO (1) WO2008127594A2 (US07794700-20100914-C00152.png)
ZA (1) ZA200906765B (US07794700-20100914-C00152.png)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2513165T3 (es) * 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
BRPI0810206A2 (pt) * 2007-04-10 2014-10-21 Exelixis Inc Método de tratar câncer
PT2374802E (pt) * 2008-11-10 2014-07-10 Kyowa Hakko Kirin Co Ltd Inibidor de produção de quinurenina
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
CN103270027A (zh) 2010-10-20 2013-08-28 默克雪兰诺日内瓦有限公司 制备取代的n-(3-氨基-喹喔啉-2-基)-磺酰胺和它们的中间体n-(3-氯-喹喔啉-2-基)-磺酰胺的方法
DE102010048800A1 (de) * 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2013040337A1 (en) * 2011-09-14 2013-03-21 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
EP2763994A4 (en) * 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
CA2853095A1 (en) * 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CN104302294A (zh) * 2011-11-01 2015-01-21 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
WO2013101964A1 (en) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
JP6193374B2 (ja) 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
RU2663999C2 (ru) 2013-10-16 2018-08-14 Шанхай Инли Фармасьютикал Ко., Лтд Конденсированное гетероциклическое соединение, способ его получения, его фармацевтическая композиция и применения
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc ANTICANCER THERAPY
KR20080049767A (ko) * 2005-08-26 2008-06-04 라보라뚜와르 세로노 에스. 에이. 피라진 유도체 및 ｐｉ３ｋ 억제제로서의 용도
ES2513165T3 (es) 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
EA016945B1 (ru) 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008101979A1 (en) * 2007-02-22 2008-08-28 Merck Serono S.A. Quinoxaline compounds and use thereof
BRPI0810206A2 (pt) 2007-04-10 2014-10-21 Exelixis Inc Método de tratar câncer
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
PL2139483T3 (pl) 2014-02-28
NI200900184A (es) 2011-09-08
KR20100019436A (ko) 2010-02-18
MY150797A (en) 2014-02-28
ECSP099723A (es) 2010-03-31
BRPI0810208A2 (pt) 2014-10-21
IL201211A (en) 2015-09-24
AU2008239668A1 (en) 2008-10-23
KR101586774B1 (ko) 2016-01-19
CR11099A (es) 2010-01-19
HRP20131081T1 (hr) 2013-12-20
EA019064B1 (ru) 2013-12-30
AU2008239668B2 (en) 2013-11-07
SV2009003390A (es) 2010-05-21
EP2139483B1 (en) 2013-09-18
HK1140141A1 (en) 2010-10-08
US20110123434A1 (en) 2011-05-26
DK2139483T3 (da) 2014-01-13
IL201211A0 (en) 2010-05-31
JP2010523669A (ja) 2010-07-15
ES2438998T3 (es) 2014-01-21
WO2008127594A3 (en) 2009-04-30
MA31335B1 (fr) 2010-04-01
WO2008127594A2 (en) 2008-10-23
TN2009000399A1 (fr) 2010-12-31
CN101959516A (zh) 2011-01-26
MX2009010929A (es) 2010-01-20
JP2014074031A (ja) 2014-04-24
ZA200906765B (en) 2010-05-26
PT2139483E (pt) 2013-12-27
GT200900263A (es) 2014-01-15
US8481001B2 (en) 2013-07-09
EP2139483B9 (en) 2014-05-21
CN103202842A (zh) 2013-07-17
ME00937B (me) 2012-06-20
EA200970935A1 (ru) 2010-04-30
NZ580009A (en) 2012-06-29
CN101959516B (zh) 2013-05-08
RS53020B (en) 2014-04-30
CY1114608T1 (el) 2016-10-05
EP2139483A2 (en) 2010-01-06
CO6140024A2 (es) 2010-03-19
UA98141C2 (ru) 2012-04-25
JP5726515B2 (ja) 2015-06-03
CA2684056A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
SI2139483T1 (sl) Kombinacijske terapije, obsegajoče PI3K-alfa kinoksalin inhibitor, za uporabo pri zdravljenju raka
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
IL219253A (en) Benzodiazepine inhibiting bromodomain for cancer treatment
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
HK1136822A1 (en) Therapeutic compounds and their use in cancer
IL229876B (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
ZA201004403B (en) Therapeutic cancer treatments
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
EP2318406A4 (en) THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES
EP2127671A4 (en) THERAPEUTIC AGENT AGAINST CANCER
PL2040753T3 (pl) Inhibitory progastryny w leczeniu raka okrężnicy
GB0724251D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
GB0607946D0 (en) Mono and combination therapy
HK1151971A1 (en) Compounds for use in the treatment of cancer
GB0607949D0 (en) Mono and combination therapy
EP1917041A4 (en) USE OF FRUCTOSE-BASED THERAPIES FOR CANCER TREATMENT
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0705517D0 (en) Therapeutic compounds and their use
GB0604794D0 (en) Spisulosine compounds for use in cancer therapy
GB0725166D0 (en) The use of ketoprofen in treating hemorrhoids